Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ (2,448)	$ 5,356
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization	5,161	2,552
Share based compensation	5,196	4,987
Deferred income taxes	(436)	(1,114)
Bad debt expense	53	292
(Increase) decrease in operating assets and increase (decrease) in operating liabilities:
Accounts receivable	(119)	(324)
Inventories - finished goods	(12,438)	10,053
Prepaid income taxes	65	(927)
Prepaid expenses and other current assets	(2,664)	(771)
Operating lease right-of-use assets, net	594	0
Accounts payable	7,929	(3,183)
Sales tax payable	(1,942)	2,291
Accrued expenses and other current liabilities	(1,258)	(1,133)
Lease liabilities	(577)	0
Deferred revenue	75	0
Net cash (used in) provided by operating activities	(2,808)	18,079
Cash flows from investing activities:
Purchase of minority interest investment in Vetster	(300)	(5,000)
Acquisition of PetCareRx, net of cash acquired	(35,859)	0
Purchases of property and equipment	(3,260)	(3,329)
Net cash used in investing activities	(39,419)	(8,329)
Cash flows from financing activities:
Dividends paid	(12,419)	(18,402)
Net cash used in financing activities	(12,419)	(18,402)
Net decrease in cash and cash equivalents	(54,646)	(8,652)
Cash and cash equivalents, at beginning of period	104,086	111,080
Cash and cash equivalents, at end of period	49,440	102,428
Supplemental disclosure of cash flow information:
Cash paid for income taxes	43	3,870
Dividends payable in accrued expenses and other current liabilities	$ 1,498	$ 1,079